Alaunos Therapeutics Inc. (TCRT)
Alaunos Therapeutics Statistics
Share Statistics
Alaunos Therapeutics has 1.6M shares outstanding. The number of shares has increased by -90% in one year.
| Shares Outstanding | 1.6M |
| Shares Change (YoY) | -90% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 1.38M |
| Failed to Deliver (FTD) Shares | 3.17K |
| FTD / Avg. Volume | 0.65% |
Short Selling Information
The latest short interest is 139.31K, so 8.7% of the outstanding shares have been sold short.
| Short Interest | 139.31K |
| Short % of Shares Out | 8.7% |
| Short % of Float | 10.09% |
| Short Ratio (days to cover) | 10.12 |
Valuation Ratios
The PE ratio is -653.64 and the forward PE ratio is -2.76. Alaunos Therapeutics's PEG ratio is 6.54.
| PE Ratio | -653.64 |
| Forward PE | -2.76 |
| PS Ratio | 305839.13 |
| Forward PS | 0 |
| PB Ratio | 1482.5 |
| P/FCF Ratio | -615.25 |
| PEG Ratio | 6.54 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Alaunos Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.98, with a Debt / Equity ratio of 0.
| Current Ratio | 3.98 |
| Quick Ratio | 3.98 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $10K |
| Profits Per Employee | $-4.68M |
| Employee Count | 1 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -83.17% in the last 52 weeks. The beta is -0.53, so Alaunos Therapeutics's price volatility has been lower than the market average.
| Beta | -0.53 |
| 52-Week Price Change | -83.17% |
| 50-Day Moving Average | 1.77 |
| 200-Day Moving Average | 2.61 |
| Relative Strength Index (RSI) | 60 |
| Average Volume (20 Days) | 487.34K |
Income Statement
In the last 12 months, Alaunos Therapeutics had revenue of 10K and earned -4.68M in profits. Earnings per share was 0.
| Revenue | 10K |
| Gross Profit | 10K |
| Operating Income | -4.81M |
| Net Income | -4.68M |
| EBITDA | -4.68M |
| EBIT | -4.68M |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 1.09M in cash and 0 in debt, giving a net cash position of 1.09M.
| Cash & Cash Equivalents | 1.09M |
| Total Debt | 0 |
| Net Cash | 1.09M |
| Retained Earnings | -920.45M |
| Total Assets | 2.75M |
| Working Capital | 2.06M |
Cash Flow
In the last 12 months, operating cash flow was -4.97M and capital expenditures 0, giving a free cash flow of -4.97M.
| Operating Cash Flow | -4.97M |
| Capital Expenditures | 0 |
| Free Cash Flow | -4.97M |
| FCF Per Share | 0 |
Margins
Gross margin is 100%, with operating and profit margins of -48120% and -46790%.
| Gross Margin | 100% |
| Operating Margin | -48120% |
| Pretax Margin | -46790% |
| Profit Margin | -46790% |
| EBITDA Margin | -46770% |
| EBIT Margin | -48120% |
| FCF Margin | -49710% |
Dividends & Yields
TCRT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for TCRT.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jul 18, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Jul 18, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -468.99 |
| Piotroski F-Score | 5 |